First human trial of AstraZeneca COVID-19 vaccine shows promise

The leaders for two of the most advanced coronavirus vaccine projects - Oxford University, in partnership with AstraZeneca labs, and China's Sinovac - will carry out clinical testing in Brazil. LONDON: AstraZeneca's experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday .

The vaccine is called AZD1222 and is being developed by AstraZeneca and scientists at Britain's University of Oxford.It did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal. "We hope this means the immune system will remember the virus, so that our vaccine will protect people for an extended period," study lead author Andrew Pollard of the University of Oxford said.

"However, we need more research before we can confirm the vaccine effectively protects against SARS-CoV-2 infection, and for how long any protection lasts," he said. AstraZeneca's is among the leading vaccine candidates against a pandemic that has claimed more than 600,000 lives, alongside others in mid and late-stage trials.These include shots being developed by China's Sinovac Biotech, another from state-owned Chinese firm Sinopharm, and one from the

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Bangladesh allows late-stage trial of China's Sinovac COVID-19 vaccineBangladesh has approved the third-phase trial of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd, officials said on Monday, as infections continue to rise in the densely-populated South Asian country. Sinovac has been looking for volunteers outside of China as the number of
Source: YahooSG - 🏆 3. / 71 Read more »